Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response

Alicia A Gingrich; Amanda R Kirane

doi:10.1016/j.soc.2020.02.012

Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response

Surg Oncol Clin N Am. 2020 Jul;29(3):467-483. doi: 10.1016/j.soc.2020.02.012.

Authors

Alicia A Gingrich¹, Amanda R Kirane²

Affiliations

¹ Department of Surgery, University of California Davis, 4501 X Street, Suite 3010, Sacramento, CA 95817, USA.
² Department of Surgery, University of California Davis, 4501 X Street, Suite 3010, Sacramento, CA 95817, USA. Electronic address: arkirane@ucdavis.edu.

PMID: 32482321
DOI: 10.1016/j.soc.2020.02.012

Abstract

Clinical outcomes for metastatic melanoma have been dramatically altered by recent developments in immunotherapy and targeted strategies, but response to these therapies is not uniform, the majority of patients do not respond, and clinical response can be self-limited. Current directions in melanoma treatment aim to leverage a combination of therapies for tumors refractory to monoimmunotherapy, to include tumor-directed strategies, such as intralesional therapy and inhibitors designed for novel targets, which may augment current systemic agents when used in combination. Here, we summarize new classes of agents and emerging multimodal combination strategies that demonstrate significant promise in future melanoma management.

Keywords: Checkpoint blockage; Combination therapy; Immunotherapy; Intralesional therapy; Metastatic melanoma.

Publication types

Review

MeSH terms

Combined Modality Therapy
Disease Management
Humans
Immunity*
Immunotherapy / methods*
Melanoma / immunology
Melanoma / pathology*
Melanoma / therapy*
Molecular Targeted Therapy / methods*
Skin Neoplasms / immunology
Skin Neoplasms / pathology*
Skin Neoplasms / therapy*